Nemes Rush Group LLC Sellas Life Sciences Group, Inc. Transaction History
Nemes Rush Group LLC
- $728 Billion
- Q2 2024
A detailed history of Nemes Rush Group LLC transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Nemes Rush Group LLC holds 10,000 shares of SLS stock, worth $11,800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$11,800
Previous $10.1 Million
17.82%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SLS
# of Institutions
37Shares Held
4.38MCall Options Held
3.27MPut Options Held
56.3K-
Vanguard Group Inc Valley Forge, PA1.79MShares$2.11 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA517KShares$610,0690.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$507,8340.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$363,9893.71% of portfolio
-
Opus Capital Group, LLC226KShares$266,7980.04% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $24.3M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...